semaglutide recall FDA Drug Recalls and Warnings: Recalls for Compounded and Tirzepatide, Wegovy; Facility Warning Letters South African regulators issue recall

The potential for GLP-1RAs to provide atheroprotective and antioxidant benefits in MS patients with high disease activity is also emerging, potentially reducing vascular risk [269]

SEMA significantly reduced HbA1c and AGE levels in diabetic rats compared to the sham control group

CMS originally planned a longer-term follow-on program called the BALANCE Model for Medicare Part D starting in 2027, but that launch has been delayed

However, compounded semaglutide lacks brand recognition, comes with regulatory uncertainty and faces tight competition from established players

In humans, fasting systemic plasma concentrations of total GLP-1 (including metabolites generated by DPP-4-mediated degradation) are typically in the range of 510 pmol/L and can increase up to 40 pmol/L in response to a meal [236]

Companies Sued For Ozempic or Other GLP-1 Injury Defendants named in GLP-1 injury lawsuits have included manufacturers, sellers and/or distributors of various GLP-1 receptor agonist medications, including: Novo Nordisk (Ozempic, Rybelsus, Wegovy, Saxenda) Eli Lilly (Mounjaro, Zepbound, Trulicity) Other GLP-1 injury defendants Ozempic GLP-1 Lawsuit & Settlement Updates Recent updates about Ozempic lawsuits and settlements include: July 2026: GLP-1 lawsuits remain active in federal and state courts